Cue Biopharma, Inc.

CUE

Cue Biopharma, Inc.

CUE

Insider Sentiment (TTM):

Last Purchase:2025-12-30Last Sale:2023-03-23Shares Purchased (TTM):323,857Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:21,297,438Shares Outstanding:4,807,494Institutional Ownership Pct.:N/A

Earnings Market Reaction:

Filing Date:2026-08-14Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	17	16	27	12	27	13	22	32	30	41	49	55
Available For Sale Securities Debt Securities Curr…	-	-	-	7	-	-	-	-	-	-	0	0
Accounts Receivable Net Current	5	5	6	0	1	0	1	3	2	1	2	2
Deposits Assets Current	0	1	1	2	0	1	1	-	-	-	0	-
Prepaid Expense And Other Assets Current	2	2	1	3	2	2	1	2	2	2	1	1
Value Added Tax Receivable Current	2	2	2	2	-	-	0	-	-	-	-	-
Assets Current	27	26	37	26	31	16	25	37	34	45	51	58
Property Plant And Equipment Net	0	0	0	0	0	1	0	1	1	1	1	1
Operating Lease Right Of Use Asset	3	3	4	5	5	4	4	4	5	6	6	7
Deposits Assets Noncurrent	1	1	1	1	2	2	2	3	3	3	3	3
Restricted Cash Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Value Added Tax Receivable Noncurrent	-	-	-	-	2	-	-	-	-	-	-	-
Assets	31	31	42	32	41	22	32	45	42	54	62	69
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	4	3	4	2	4	4	3	6	4	4	4	2
Accrued Liabilities Current	15	1	2	2	2	4	3	3	5	5	4	5
Other Loans Payable	-	-	-	-	-	1	-	-	-	-	-	-
Operating Lease Liability Current	2	2	2	2	2	4	4	3	3	3	3	3
Other Long Term Debt Current	-	-	0	1	2	3	4	4	4	4	4	4
Other Loans Payable Current	1	1	1	-	-	-	0	-	-	-	-	-
Liabilities Current	21	7	13	16	19	15	14	17	16	18	17	17
Operating Lease Liability Noncurrent	1	2	2	3	3	0	1	1	2	3	3	4
Long Term Debt Noncurrent	-	-	-	-	-	-	0	1	2	3	4	5
Other Loans Payable Long Term	-	-	-	0	0	-	-	-	-	-	-	-
Liabilities	28	9	16	18	23	16	15	19	21	24	24	26
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	529	395	395	383	381	361	359	358	345	344	338	330
Accumulated Other Comprehensive Income Loss Net Of…	-	-	-	0	-	-	-	-	-	-	0	0
Retained Earnings Accumulated Deficit	-527	-374	-368	-370	-363	-354	-342	-332	-324	-314	-301	-288
Stockholders Equity	2	22	26	13	18	7	17	25	22	30	37	43
Liabilities And Stockholders Equity	31	31	42	32	41	22	32	45	42	54	62	69
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	300	300	300	300	300	200	200	100	100	100	100	100
Common Stock Shares Issued	5	3	3	3	3	0	2	2	2	2	2	2
Shares Outstanding	5	3	3	3	3	2	2	2	2	2	2	2

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	16.30%	11.57%	20.02%	-	-	-	-	-	-	-	-	-
2025	-14.65%	-7.46%	-1.86%	-1.27%	-7.72%	-2.78%	-17.81%	-49.55%	-49.85%	60.90%	273.93%	214.74%
2024	-14.88%	-35.25%	-65.01%	-4.84%	87.10%	145.16%	-26.67%	-7.33%	-3.33%	-13.83%	-27.44%	-23.05%
2023	-	-	-	-	-	-	-0.41%	22.04%	14.29%	-17.46%	-9.52%	-28.04%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	1.25	3.57	2.74	1.66	1.60	1.03	1.84	2.22	2.06	2.47	3.01	3.34
Quick Ratio	1.16	3.34	2.64	1.46	1.48	0.91	1.78	2.12	1.94	2.35	2.96	3.27
Working Capital	5.41M	19.00M	23.49M	10.30M	11.59M	433.00K	11.45M	20.47M	17.44M	26.58M	34.37M	40.31M
Leverage & Debt
Debt to Equity	12.29	0.43	0.60	1.39	1.24	2.38	0.84	0.77	0.96	0.80	0.66	0.61
Interest Coverage TTM	-127.31	-24.03	-32.90	-43.37	-39.34	-33.44	-25.59	-21.89	-19.76	-19.92	-19.60	-20.96
Debt Ratio	0.92	0.30	0.37	0.58	0.55	0.70	0.46	0.43	0.49	0.44	0.40	0.38
Efficiency & Turnover
Asset Turnover TTM	1.05	1.23	0.74	0.19	0.20	0.21	0.20	0.17	0.14	0.10	0.07	0.05
Days Sales Outstanding TTM	28.64	59.67	43.13	90.97	52.39	-	51.94	92.15	65.60	41.49	58.34	117.38
Receivables Turnover TTM	12.74	6.12	8.46	4.01	6.97	-	7.03	3.96	5.56	8.80	6.26	3.11
Per Share Metrics
Diluted EPS TTM	-25.88	-4.06	-8.43	-11.22	-12.22	-16.40	-21.68	-26.15	-28.10	-30.34	-33.30	-33.61
Free Cash Flow Per Share TTM	-7.52	-5.17	-7.01	-6.47	-6.36	-14.09	-19.40	-22.47	-23.10	-23.66	-26.23	-25.60
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-262.03%	-59.90%	-96.67%	-537.51%	-475.24%	-514.72%	-446.86%	-479.43%	-582.24%	-732.72%	-949.89%	-1,392.20%
Net Profit Margin TTM	-435.83%	-59.65%	-96.85%	-530.75%	-469.35%	-507.87%	-437.97%	-468.02%	-566.02%	-711.84%	-924.10%	-1,358.40%
Growth Metrics
Net Revenue Growth (1Y)	354.37%	309.60%	195.75%	-25.51%	-0.11%	13.83%	69.16%	149.53%	363.98%	1,525.00%	340.96%	-59.14%
Net Income Growth (1Y)	321.93%	-51.89%	-34.60%	-15.53%	-17.17%	-18.78%	-19.83%	-14.03%	-9.42%	-3.65%	-4.30%	10.87%
EPS Growth (1Y)	111.73%	-75.23%	-61.11%	-57.10%	-56.51%	-45.95%	-34.88%	-22.20%	-19.13%	-13.03%	-25.43%	-15.38%
Valuation Metrics
P/E TTM	-1.22	-1.70	-1.09	-1.92	-1.67	-1.67	-1.51	-0.87	-1.32	-1.87	-2.38	-2.05
P/B TTM	86.63	1.54	1.09	5.47	3.59	10.28	3.51	1.53	2.87	3.11	3.25	2.50
P/S TTM	5.31	1.01	1.05	10.20	7.86	8.47	6.60	4.06	7.49	13.30	21.98	27.88
Market Cap	200.12M	33.17M	28.86M	72.45M	65.10M	67.65M	61.34M	38.74M	62.15M	93.40M	120.67M	106.52M
Enterprise Value	182.73M	16.79M	1.73M	60.75M	37.61M	54.51M	38.88M	7.65M	34.41M	55.61M	76.36M	56.99M
Calculated Values
Free Cash Flow TTM	-47.67M	-24.85M	-22.11M	-21.74M	-20.25M	-34.88M	-36.40M	-38.33M	-38.60M	-38.97M	-39.96M	-39.52M
Net Debt	-17.39M	-16.38M	-27.14M	-11.70M	-27.49M	-13.14M	-22.46M	-31.09M	-27.74M	-37.79M	-44.31M	-49.53M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-12-30Purchase

Owner: Sarraf, Pasha

Title: -

Shares: 323,857

Price/Share: $0.31

Value: $100,395.67

Shares Owned: 323,857

Relationship: Director

Ownership: Direct

2024-12-16Purchase

Owner: Passeri, Daniel R

Title: CHIEF EXECUTIVE OFFICER

Shares: 30,000

Price/Share: $1.03

Value: $30,900.00

Shares Owned: 164,578

Relationship: Director,Officer

Ownership: Direct

2023-08-25Purchase

Owner: Suri, Anish

Title: PRESIDENT AND CSO

Shares: 4,000

Price/Share: $2.76

Value: $11,040.00

Shares Owned: 135,638

Relationship: Officer

Ownership: Direct

2023-08-14Purchase

Owner: Passeri, Daniel R

Title: CHIEF EXECUTIVE OFFICER

Shares: 3,000

Price/Share: $2.86

Value: $8,580.00

Shares Owned: 134,578

Relationship: Director,Officer

Ownership: Direct

2023-03-23Sale

Owner: Kiener, Peter A

Title: -

Shares: 9,325

Price/Share: $3.28

Value: $30,586.00

Shares Owned: 357

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-12-30	Sarraf, Pasha	Director	-	Direct	Purchase	323,857	0.31	$100,395.67	323,857	4
2024-12-16	Passeri, Daniel R	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Purchase	30,000	1.03	$30,900.00	164,578	4
2023-08-25	Suri, Anish	Officer	PRESIDENT AND CSO	Direct	Purchase	4,000	2.76	$11,040.00	135,638	4
2023-08-14	Passeri, Daniel R	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Purchase	3,000	2.86	$8,580.00	134,578	4
2023-03-23	Kiener, Peter A	Director	-	Direct	Sale	9,325	3.28	$30,586.00	357	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

Inst. Shares: 21,297,438

Shares Outstanding: 4,807,494

2025-12-31

22.88%

Inst. Shares: 21,676,036

Shares Outstanding: 94,731,768

2025-09-30

17.86%

Inst. Shares: 18,018,987

Shares Outstanding: 100,869,349

2025-06-30

18.12%

Inst. Shares: 17,293,197

Shares Outstanding: 95,459,401

2025-03-31

Inst. Shares: 11,242,883

Shares Outstanding: 2,475,156

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	21,297,438	4,807,494	-
2025-12-31	21,676,036	94,731,768	22.88%
2025-09-30	18,018,987	100,869,349	17.86%
2025-06-30	17,293,197	95,459,401	18.12%
2025-03-31	11,242,883	2,475,156	-
2024-12-31	11,510,743	56,328,348	20.44%
2024-09-30	13,588,866	51,229,701	26.53%
2024-06-30	13,426,310	50,174,756	26.76%
2024-03-31	15,816,622	49,466,711	31.97%
2023-12-31	14,603,512	45,754,794	31.92%
2023-09-30	13,453,254	46,358,555	29.02%
2023-06-30	13,500,142	44,798,760	30.14%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Cue Biopharma, Inc. (CUE) — SEC Financial Statements & Analysis

Cue Biopharma, Inc. (CUE) is a pharmaceutical preparations company, incorporated in DE. Cue Biopharma, Inc. trades on Nasdaq as: CUE. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Cue Biopharma, Inc. reported a 354.37% year-over-year revenue growth, a Debt-to-Equity ratio of 12.29x, a Price-to-Sales (P/S) ratio of 5.31x (TTM), a Price-to-Book (P/B) ratio of 86.63x (TTM), at a market cap of $200.12M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 354.37%
Debt To Equity: 12.29x
P/S TTM: 5.31x
P/B TTM: 86.63x
Market Cap: $200.12M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Cue Biopharma, Inc. in?

Cue Biopharma, Inc. (CUE) operates in the Pharmaceutical Preparations industry.

What is CUE's market cap?

Cue Biopharma, Inc. (CUE) has a market capitalization of $200.12M as of 2026-06-30.

What exchange does CUE trade on?

Cue Biopharma, Inc. (CUE) trades on the Nasdaq.

Where is Cue Biopharma, Inc. incorporated?

Cue Biopharma, Inc. is incorporated in DE.